By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.

The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.